Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.

Fiche publication


Date publication

mars 2021

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier, Pr BORG Christophe, Pr WESTEEL Virginie, Mme BOUARD Adeline, Dr MANSI Laura, Dr VIENOT Angélique, Dr DAGUINDAU Etienne, Dr KROEMER Marie, Dr NARDIN Charlée


Tous les auteurs :
Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G, Vienot A, Nardin C, Bazan F, Lepiller Q, Westeel V, Adotévi O, Borg C, Kroemer M

Résumé

Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients' immune system responds to SARS-CoV-2 virus.

Mots clés

Cancer patients, Immune T cell response, SARS-CoV-2 antibodies, SARS-CoV-2 infection

Référence

Eur J Cancer. 2021 Mar 26;150:1-9